Paper42953404PubMed
Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.
Liu Q and 7 others. Front Cell Dev Biol, 2026.
Cite this record
ConductScience Library. Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies. Papers, record 42953404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42953404
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies.
- Journal
- Front Cell Dev Biol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-30
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References160
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22768835 | Metabolic regulation of epigenetics. | Cell Metab | 2012 | https://conductscience.org/library/papers/22768835 | PubMed |
| 2 | 30723290 | Epigenetic therapy in immune-oncology. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/30723290 | PubMed |
| 3 | 41388204 | Author Correction: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. | Nature | 2026 | https://conductscience.org/library/papers/41388204 | PubMed |
| 4 | 39075148 | Epigenome editing technologies for discovery and medicine. | Nat Biotechnol | 2024 | https://conductscience.org/library/papers/39075148 | PubMed |
| 5 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 6 | 30725423 | Is the Hoffman Effect for Methionine Overuse Analogous to the Warburg Effect for Glucose Overuse in Cancer? | Methods Mol Biol | 2019 | https://conductscience.org/library/papers/30725423 | PubMed |
| 7 | 30613774 | Improving the metabolic fidelity of cancer models with a physiological cell culture medium. | Sci Adv | 2019 | https://conductscience.org/library/papers/30613774 | PubMed |
| 8 | 41596524 | Molecular and Immune Mechanisms Governing Cancer Metastasis, Including Dormancy, Microenvironmental Niches, and Tumor-Specific Programs. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596524 | PubMed |
| 9 | 38490978 | Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. | Cell Death Discov | 2024 | https://conductscience.org/library/papers/38490978 | PubMed |
| 10 | 32854717 | Roles of METTL3 in cancer: mechanisms and therapeutic targeting. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32854717 | PubMed |
| 11 | 28581528 | DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells. | Oncogene | 2017 | https://conductscience.org/library/papers/28581528 | PubMed |
| 12 | 31564637 | An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. | Cancer Cell | 2019 | https://conductscience.org/library/papers/31564637 | PubMed |
| 13 | 29889360 | Cell cycle regulation of folate-mediated one-carbon metabolism. | Wiley Interdiscip Rev Syst Biol Med | 2018 | https://conductscience.org/library/papers/29889360 | PubMed |
| 14 | 40028035 | Treating human cancer by targeting EZH2. | Genes Dis | 2025 | https://conductscience.org/library/papers/40028035 | PubMed |
| 15 | 26411344 | Histone Methylation Dynamics and Gene Regulation Occur through the Sensing of One-Carbon Metabolism. | Cell Metab | 2015 | https://conductscience.org/library/papers/26411344 | PubMed |
| 16 | 36979768 | Epigallocatechin Gallate (EGCG), an Active Phenolic Compound of Green Tea, Inhibits Tumor Growth of Head and Neck Cancer Cells by Targeting DNA Hypermethylation. | Biomedicines | 2023 | https://conductscience.org/library/papers/36979768 | PubMed |
| 17 | 33491748 | Serine, glycine and one‑carbon metabolism in cancer (Review). | Int J Oncol | 2021 | https://conductscience.org/library/papers/33491748 | PubMed |
| 18 | 32276408 | Methionine Dependence of Cancer. | Biomolecules | 2020 | https://conductscience.org/library/papers/32276408 | PubMed |
| 19 | 41388311 | EF24 targets METTL3 to reprogram m6A methylation and induce ferroptosis: an epitranscriptomic mechanism with therapeutical potential for glioma. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/41388311 | PubMed |
| 20 | 41223330 | EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression. | Cancer Res | 2026 | https://conductscience.org/library/papers/41223330 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42953404
GET https://conductscience.org/api/papers/v1/42953404/references?page=2